We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with the potential to reach the market in 2025 or 2026 for melanoma, pyruvate dehydrogenase complex deficiency, and retinitis pigmentosa.
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- A review of Food and Drug Administration (FDA) approvals from 2024.
- A spotlight on treatment landscapes and pipelines for hemophilia and myasthenia gravis.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
